| TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery (NCT04197687) | Academic and Community Cancer Research United | 2020-02-20 |
| Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy (NCT03872388) | M.D. Anderson Cancer Center | 2019-09-23 |
| Patient Reported Outcomes, Smart Pill Bottle and Teleheath for Endocrine Therapy Adherence (NCT04054557) | Thomas Jefferson University | 2019-07-31 |
| SCOUT Reflector for Tagging Lymph Nodes for Targeted Removal in Patients With Breast Cancer (NCT03411070) | Jonsson Comprehensive Cancer Center | 2019-04-07 |
| Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery (NCT03317405) | National Cancer Institute (NCI) | 2018-10-31 |
| Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib (NCT03094052) | University of California, San Francisco | 2018-10-09 |
| Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability (NCT03428802) | Rutgers, The State University of New Jersey | 2018-03-08 |
| Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer (NCT03101748) | M.D. Anderson Cancer Center | 2018-02-19 |
| Hypofractionated Radiation Therapy in Preventing Recurrence in Patients With Breast Cancer After Surgery (NCT03324802) | Mayo Clinic | 2018-02-07 |
| Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer (NCT03106415) | Mayo Clinic | 2017-09-27 |
| Kindness Interventions in Enhancing Well-Being in Breast Cancer Survivors (NCT03319342) | Jonsson Comprehensive Cancer Center | 2017-07-11 |
| Magseed Magnetic Marker in Locating Axillary Lymph Nodes in Patients With Breast Cancer Undergoing Surgery (NCT03038152) | M.D. Anderson Cancer Center | 2017-04-11 |
| Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer (NCT03012100) | Academic and Community Cancer Research United | 2017-03-31 |
| Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC (NCT02593175) | M.D. Anderson Cancer Center | 2016-11-03 |
| Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer (NCT02689427) | M.D. Anderson Cancer Center | 2016-09-22 |
| Electroacupuncture Therapy in Reducing Chronic Pain in Patients After Breast Cancer Treatment (NCT02754752) | M.D. Anderson Cancer Center | 2016-09-13 |
| A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors (NCT02498613) | National Cancer Institute (NCI) | 2016-08-31 |
| Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer (NCT02474173) | National Cancer Institute (NCI) | 2016-01-15 |
| Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative (NCT02276443) | M.D. Anderson Cancer Center | 2015-11-09 |
| Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer (NCT02311933) | National Cancer Institute (NCI) | 2015-05-28 |
| Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients (NCT02152943) | M.D. Anderson Cancer Center | 2014-07-17 |
| Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer (NCT02003209) | National Cancer Institute (NCI) | 2014-02-18 |
| The Role of Lifestyle Factors in Breast Cancer-Related Outcomes (NCT02079662) | M.D. Anderson Cancer Center | 2013-06-13 |
| Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease (NCT01552434) | M.D. Anderson Cancer Center | 2012-10-16 |
| Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction (NCT01638533) | National Cancer Institute (NCI) | 2012-08-03 |
| Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer (NCT01463072) | City of Hope Medical Center | 2012-06-19 |
| Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer (NCT01275677) | National Cancer Institute (NCI) | 2011-02-08 |
| Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery (NCT00861705) | National Cancer Institute (NCI) | 2009-07-21 |
| Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery (NCT00770809) | National Cancer Institute (NCI) | 2009-02-24 |
| Temsirolimus in Treating Patients With Locally Advanced or Metastatic Breast Cancer (NCT00376688) | National Cancer Institute (NCI) | 2006-07-11 |
| Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer (NCT00005970) | National Cancer Institute (NCI) | 2000-05-19 |